Evidence-Based Medicine Guidelines
Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Iloprost and Cisaprost for Raynaud's Phenomenon in Progressive Systemic Sclerosis." Evidence-Based Medicine Guidelines, Duodecim Medical Publications Limited, 2019. Evidence Central, evidence.unboundmedicine.com/evidence/view/EBMG/451691/all/Iloprost_and_cisaprost_for_Raynaud's_phenomenon_in_progressive_systemic_sclerosis.
Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis. Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. https://evidence.unboundmedicine.com/evidence/view/EBMG/451691/all/Iloprost_and_cisaprost_for_Raynaud's_phenomenon_in_progressive_systemic_sclerosis. Accessed September 15, 2024.
Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis. (2019). In Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited. https://evidence.unboundmedicine.com/evidence/view/EBMG/451691/all/Iloprost_and_cisaprost_for_Raynaud's_phenomenon_in_progressive_systemic_sclerosis
Iloprost and Cisaprost for Raynaud's Phenomenon in Progressive Systemic Sclerosis [Internet]. In: Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. [cited 2024 September 15]. Available from: https://evidence.unboundmedicine.com/evidence/view/EBMG/451691/all/Iloprost_and_cisaprost_for_Raynaud's_phenomenon_in_progressive_systemic_sclerosis.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis
ID - 451691
BT - Evidence-Based Medicine Guidelines
UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/451691/all/Iloprost_and_cisaprost_for_Raynaud's_phenomenon_in_progressive_systemic_sclerosis
PB - Duodecim Medical Publications Limited
DB - Evidence Central
DP - Unbound Medicine
ER -
